GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Clasificación en acciones
#3668
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Precio por acción
$27.17
Capitalización bursátil
$4.60B
Cambio (1 día)
-1.33%
Cambio (1 año)
-13.30%
País
IN
Comercio GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Categoría
Healthcare
Número de acciones en circulación de GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Número de acciones en circulación al June 2026: 169.41M
Según los últimos informes financieros y el precio de las acciones de GlaxoSmithKline Pharmaceuticals Limited, el número actual de acciones en circulación es 169.41M. Al final de March 2024, la empresa tenía 169.41M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de GlaxoSmithKline Pharmaceuticals Limited (GLAXO) desde 2004 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 169.41M | 0.00% |
| 2025 | 169.41M | 0.00% |
| 2024 | 169.41M | -0.50% |
| 2023 | 170.26M | -4.88% |
| 2022 | 178.98M | 5.65% |
| 2021 | 169.41M | 0.00% |
| 2020 | 169.41M | 0.00% |
| 2019 | 169.41M | 0.00% |
| 2018 | 169.41M | 0.00% |
| 2017 | 169.41M | 0.00% |
| 2016 | 169.41M | 0.00% |
| 2015 | 169.41M | 0.00% |
| 2013 | 169.41M | 0.00% |
| 2012 | 169.41M | 0.00% |
| 2011 | 169.41M | 0.00% |
| 2010 | 169.41M | 0.00% |
| 2009 | 169.41M | 0.00% |
| 2008 | 169.41M | 0.00% |
| 2007 | 169.41M | 0.00% |
| 2006 | 169.41M | -1.29% |
| 2005 | 171.62M | -1.73% |
| 2004 | 174.65M | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 892.40M | 426.78% |
US
|
|
| 2.45B | 1,344.78% |
US
|
|
| 1.77B | 945.41% |
US
|
|
| 0.00 | -100.00% |
US
|
|
| 796.00M | 369.88% |
CH
|
